That’s all good TR. All we know there were 6 or so NDA’s a while back and you wonder how many kept the interest, Ltr is in pursuit of the best fit partner. Another point - we cannot bring forward the looming massive supply deficit, Ltr wants to play acc to that, it’s like a boxer, dance around the opponent to tire him out and knock him down on the last bell.
As a ceo, he’d be interested in everything- progressing the project, forming the team, getting the money amd most importantly SELLING aka Share price.
Ltr lacks the selling aspect of this project, otherwise how could we be 4x to 10x undervalued compared to minnows in the sector. It’s repeatedly mentioned they’re doing it methodically without hype that peers keep spruiking ann after ann. But we cannot be too conservative
Hence, while we can accept they’re doing a great job based on updates 1 & 2, we need to step up our exposure to the market - we only have bridge street drum rolling for us. It’s all there in the preso
-WOF to produce premium grades, not the base 6.0%
-ESGE, UG produces much less tailings and env impact,
-tier 1 with massive upside from open extensions and undrilled targets
-top location and available infrastructure
-downstream integration
......so why is the market not listening?
Whilst the dfs gains solid progress, it’s good to see the exploration side stepped up
-now Buldania, that’s what I like, keep drilling till we hit the next tier 1, with at least 4 targets now - Mt Yule, Bindi bindi, koojan valley and Buldania. It’s hard to imagine we’ll not get at least 1 more major discovery in the next 12-18 months.
The KV intrinsic value locked in + big exploration = that’s what we need to SELL, SELL, SELL.
- Forums
- ASX - By Stock
- LTR
- Ann: Tony Ottaviano Commences as Managing Director
Ann: Tony Ottaviano Commences as Managing Director, page-51
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LTR (ASX) to my watchlist
(20min delay)
|
|||||
Last
98.8¢ |
Change
-0.013(1.25%) |
Mkt cap ! $2.418B |
Open | High | Low | Value | Volume |
$1.03 | $1.03 | 98.0¢ | $8.424M | 8.423M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 140321 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 113923 | 30 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 61622 | 0.985 |
47 | 462406 | 0.980 |
14 | 342417 | 0.975 |
19 | 156167 | 0.970 |
6 | 565013 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 100888 | 30 |
0.995 | 100015 | 14 |
1.000 | 282198 | 21 |
1.005 | 191467 | 11 |
1.010 | 331038 | 20 |
Last trade - 14.46pm 15/07/2024 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online